Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib trial evaluating NXP900 as monotherapy in YES1/SRC-driven solid tumors, and in combination with EGFR and ALK inhibitors, in patients with non-small cell lung cancer

Next Previous
Trial Profile

A Phase Ib trial evaluating NXP900 as monotherapy in YES1/SRC-driven solid tumors, and in combination with EGFR and ALK inhibitors, in patients with non-small cell lung cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anaplastic lymphoma kinase inhibitors (Primary) ; Epidermal growth factor receptor antagonists (Primary) ; NXP 900 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 08 Jul 2025 According to Nuvectis Pharma media release, this study is , set to begin in the coming weeks.
  • 29 Apr 2025 According to Nuvectis Pharma media release, the Phase 1b portion of the single agent study is expected to commence shortly after the conclusion of the dose escalation phase,
  • 28 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top